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Retinol binding protein-4 (RBP4) is a serumprotein involved in the transport of vitamin A. It is known
to be produced by the liver andwhite adipose tissue. RBP4 release bywhite fat has been proposed to
induce insulin resistance.Weanalyzed the regulationandproductionofRBP4 inbrownadipose tissue.
RBP4 gene expression is induced in brown fat frommice exposed to cold or treated with peroxisome
proliferator-activatedreceptor(PPAR)agonists. Inbrownadipocytes inculture,norepinephrine,cAMP,
and activators of PPAR and PPAR induced RBP4 gene expression and RBP4 protein release. The
induction of RBP4 gene expression by norepinephrine required intact PPAR-dependent pathways, as
evidenced by impaired response of the RBP4 gene expression to norepinephrine in PPAR-null brown
adipocytes or in the presence of inhibitors of PPAR and PPAR. PPAR and norepinephrine can also
inducetheRBP4geneinwhiteadipocytes,andoverexpressionofPPARconfersregulationbythisPPAR
subtype towhite adipocytes. The RBP4 gene promoter transcription is activated by cAMP, PPAR, and
PPAR. This is mediated by a PPAR-responsive element capable of binding PPAR and PPAR and
required also for activationby cAMP. The inductionof theRBP4gene expressionbynorepinephrine in
brown adipocytes is protein synthesis dependent and requires PPAR-coactivator-1-, which acts as a
norepinephine-induced coactivator of PPAR on the RBP4 gene.We conclude that PPAR- and PPAR-
mediated signaling controls RBP4 gene expression and releases in brown adipose tissue, and thermo-
genic activation induces RBP4 gene expression in brown fat through mechanisms involving PPAR-
coactivator-1- coactivation of PPAR signaling. (Endocrinology 153: 1162–1173, 2012)
Retinol binding protein-4 (RBP4) is a serum proteinwhose primary recognized function is the transport of
vitamin A (1). The liver is the main site of RBP4 produc-
tion, whereas other tissues, particularly white adipose tis-
sue (WAT), have been reported to contribute also toRBP4
synthesis and release (2). RBP4 has been proposed to act
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as an adipokine, i.e. a protein released by adipose tissuewith
regulatory functions distinct from its role in vitamin A ho-
meostasis (3). A negative correlation between RBP4 levels
(and, specifically, synthesis inWAT) and overall insulin sen-
sitivityhasbeen reported in several rodentmodels ofobesity,
and ithasbeenproposed thatRBP4releasedbyWATactson
liver as a systemic signal promoting insulin resistance. In hu-
mans, obesity and the associated insulin resistancehavebeen
described as being associated with abnormally high RBP4
protein levels in serum, whereas insulin sensitization
achieved viaweight loss or exercise appears to reduce serum
RBP4 levels (4). However, not all studies in humans have
confirmed the relationship of obesity and insulin resistance
with RBP4 levels (5–9), and the role of RBP4 as a putative
adipokine inducing insulin resistance remains controversial.
Moreover, it has been recently reported that the RBP4-vita-
minAcomplex inhibitscellular insulinresponses throughthe
interaction with the membrane protein stimulated by reti-
noic acid 6 present in the cell surface (10).
The two main types of adipose tissue in mammals,
WATandbrownadipose tissue (BAT) play opposing roles
in energy balance. WAT is an energy-storing tissue, and
BAT constitutes a site of energy expenditure due to its
thermogenic capacity. Both types of adipose tissue are
present in substantial amounts in adult rodents. In adult
humans, WAT is predominant, but BAT has been recog-
nized recently to have also a relevant presence (11, 12).
Both types of adipose tissue store vitamin A derivatives
and have functions in metabolism of retinoids, including
release of retinol (13). All-trans retinoic acid acts usually
as an antiadipogenic agent in brown and white adipocyte
differentiation (14, 15). However, retinoids participate in
the differential development of both types of adipose tis-
sues. Thus, all-trans retinoic acid, acting through retinoic
acid receptors (RAR), is a powerful inducer uncoupling
protein-1 (UCP1) expression, the specific marker of
brown-vs.-white fat and responsible for thermogenic
function (16).On theotherhand, activationof the retinoid
X receptor (RXR) by 9-cis retinoic acid favors brown and
white adipogenesis through activation of the RXRmoiety
of the adipogenic peroxisome proliferator-activated re-
ceptor (PPAR)/RXR heterodimers (17). PPAR is highly
expressed in BAT,whereas expression inWAT is very low
(18). PPAR controls the transcription of genes for lipid
catabolism in brown fat as well as UCP1 gene transcrip-
tion, and it has been proposed that it establishes a link
between lipid oxidation and thermogenesis in BAT (19).
The major pathway of control of brown fat-specific
thermogenic activity involves the action of norepineph-
rine, released by the sympathetic nervous system (20). The
activation of -adrenergic receptors leads to a rise in in-
tracellular cAMP, which mediates most of the thermo-
genic responses of the brown adipocyte, i.e. enhanced li-
polysis and induction of UCP1 gene expression.
The molecular signals controlling RBP4 gene expres-
sion and synthesis in adipose tissues are poorly under-
stood. Treatment of rodents with rosiglitazone, an acti-
vator of PPAR, has been reported to reduce RBP4 gene
expression in WAT, an effect contributing to the insulin
sensitizing effects of this drug (3). However, other reports
in humans do not support such an effect, and treatment of
human patients with the thiazolidinedione (TZD) piogli-
tazone, another activator of PPAR, has been reported to
increase RBP4 gene expression in WAT (8, 21).
In the present study, we show that RBP4 gene expres-
sion is under the control of PPAR and PPAR-mediated
regulation as well as by noradrenergic, cAMP-mediated,
stimulus involving PPAR-coactivator-1- (PGC-1) in
brown adipocytes These pathways of control may con-
tribute to the differential regulation of RBP4 gene expres-
sion and protein release by BAT and WAT.
Materials and Methods
Wy14,643, bezafibrate, GW7647, GW501516, GW6471,
GW9662, all-trans and9-cis retinoic acid, norepinephrine, dibu-
tyryl-cAMP, and cycloheximide were from Sigma (St. Louis,
MO). Rosiglitazone was from Cayman (Ann Arbor, MI).
GW7647 and 4-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-
2-naphthalenyl)-1-propenyl]benzoicacid(TTNPB)werefromToc-
ris (Ellisville, MO).
The care and use of mice were in accordance with the Euro-
pean Community Council Directive 86/609/EEC. For studies in
lactating dams, Swiss mice 15 d after parturition were injected
with a single dose of Wy14,643 [50 g/g body weight (bw)] or
bezafibrate (100 g/g bw) in 20% dimethylsulfoxide/saline, or
equivalent volumes of vehicle solution, and killed 6 h later. To
determine the effects of cold exposure, two-month-old PPAR-
null mice and strain-matched wild-type mice were acclimated to
a thermoneutral temperature (28 C) for 1 wk and then exposed
to 4 C for 24 h. Interscapular BAT, periovarian WAT, and liver
were dissected for further analysis.
RNAwas extracted fromBAT,WAT, liver, and cultured cells
(RNAeasy kit; QIAGEN, Valencia, CA). RT was performed in
20l, using randomhexamer primers (Applied Biosystems, Fos-
ter City, CA) and 0.5 g of RNA. PCR were conducted in the
ABI/Prism-7700 Sequence-Detector System using 25 l of reac-
tion mixture containing 1 l of cDNA, 12.5 l of TaqMan Uni-
versal PCR Master Mix, 250 nM probes, and 900 nM primers
from the following Assays-on-Demand (Applied Biosystems) kits:
Mm00803266, mouse RBP4; Hs00198830, human RBP4;
Mm00447183, PGC-1; andHs99999901, 18S rRNA.Each sam-
ple was run in duplicate, and the mean value of the duplicate was
normalized to that of the 18S rRNA gene using the comparative
(2CT) method following the manufacturer’s instructions.
Primary brown adipocytes were differentiated in culture as
described previously (16). Brown adipocytes were exposed to
treatments, and cells and medium were harvested 24 h later,
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unless otherwise indicated. The HIB-1B brown adipocyte cell
line was cultured as reported elsewhere (22). Primary cultures of
mouse white adipocytes were performed using preadipocytes
isolated from mouse sc WAT, as described (23). Experiments
were performed on d 12 of differentiation, and cells and medium
were harvested 24 h after treatment. SGBS human adipocyte
cells were cultured and differentiated as already reported (24), and
experiments were performed on d 12 after induction of differenti-
ation, when more than 70% cells were differentiated.
Mouse embryonic fibroblasts (MEF) were isolated from 13-
d-old (embryonic age) wild-type and PGC-1-null mice (kindly
provided by B. Spiegelman) according to standard procedures,
and adipogenic differentiation of MEF was achieved as already
described, with slight modifications (25, 26). Experiments were
performedwhen 80–90%of the cells were differentiated, on the
basis of acquisition of adipocyte morphology.
The plasmids 1192-RBP4-Luc, 535-RBP4-Luc, and
285-RBP4-Luc, inwhich the corresponding humanRBP4 pro-
moter fragments drive Firefly luciferase, have been described
previously (27). The plasmid1192-Mut-RBP4-Luc is a version
of 1192-RBP4-Luc, in which point mutations to disrupt the
putative PPAR-responsive element at position 765/745 had
been included. The point mutant construct was generated using
a QuikChange Site-Directed Mutagenesis kit (Stratagene, La
Jolla, CA), the forward primer 5-GAA ACT AAA GAA CAA
ATA TTG Aagc GAG GGa cCC ACA ACG CTC CTG AAA
GAGAG-3, and 5-CTCTCTTTCAGGAGCGTTGTGGGT
CCC TCG CTT CAA TAT TTGTTCTTTAGTTTC-3 (lower
case indicates the mutated base pairs), the complementary re-
verse primer. The plasmids were transfected into HIB-1B cells
using FuGENE 6 (Roche, Indianapolis, IN). Each point was as-
sayed in triplicate and contained 0.3 g of RBP4-Luc reporter
plasmid, 0.5 ng of the expression vector pRL-CMV (Promega,
Madison, WI), and, when indicated, 0.06 g of pSG5-PPAR,
pSG5-PPAR, or pSV-PGC-1. Cells were incubated for 48 h
after transfectionand,when indicated, treated for24hwith1M
GW7647, 10 M rosiglitazone, or 1 mM dibutyryl-cAMP. Lu-
ciferase activities were measured using the Dual-Luciferase-Re-
porter assay (Promega). Firefly luciferase activity was normal-
ized for transfection efficiency using Renilla luciferase as an
internal control.
Differentiated primary brown adipocytes were transduced
with an adenoviral vector expressing RNA interference against
PGC-1 (28) or a scrambled RNA sequence as a control. Mul-
tiplicity of infection was 200, and cells were exposed 24 h after
transduction to 0.5 M norepinephrine for 6 h. Differentiated
SGBS adipocytes were transduced with adenoviral vectors driv-
ing human PPAR (AdCMV-hPPAR) (29), murine PGC-1
(AdCMV-PGC-1, provided by B. Spiegelman), or green fluo-
rescent protein (GFP) (AdCMV-GFP, control) at amultiplicity of
infection of 400, for 4 h. Experiments were performed after fur-
ther incubation in differentiation medium for 48 h. Efficiency of
transduction was approximately 80%, on the basis of GFP flu-
orescence.Cellswere treated for 24hwith1MGW7647, 10M
rosiglitazone, or vehicle (dimethylsulfoxide).
Immunoblot analysis of RBP4 protein in cell culture medium
(35 l) was performed using 13% SDS-PAGE, RBP4 antiserum
reacting against human or mouse RBP4 (1:2000; Alexis, San
Diego, CA), and the enhanced chemiluminescence detection kit
(Amersham, Piscataway, NJ). Quantitative analysis was per-
formed by densitometry (Phoretics ID Software, Newcastle,
UK). Quantification of mouse RBP4 plasma levels was per-
formed using a specific ELISA kit (AdipoGen, Incheon, Korea).
Chromatin immunoprecipitation (ChIP) experiments were
performed as described elsewhere (30). HIB-1B cells were trans-
fected with the RBP4 promoter constructs, pSG5-PPAR or
pSG5-PPAR, and exposed to 1 M GW7647 or 10 M rosigli-
tazone, respectively, as described above. Immunoprecipitation
was carried out using anti-PPAR (sc-9000; SantaCruz Biotech-
nology, Inc., Santa Cruz, CA) or anti-PPAR (sc-7196; Santa
Cruz Biotechnology, Inc.) antibodies or an equal amount of an
unrelated immunoglobulin (Sigma). Input DNA and immuno-
precipitated DNA were analyzed by quantitative PCR using
SYBR green fluorescent dye and the following primers encom-
passing the putative PPAR-responsive region in the RBP4 gene:
forward, 5-ACC AGG GTT GCG TTT CTG GAG AAT-3;
reverse, 5-TCTGAGGTCCACTTGTGCAGGAAT-3. Prim-
ers amplifying a 237-bp fragment of the cyclophilin-A gene, used
as control, were: forward, 5-CCA TCC AGC CAT TCA GTC
TT-3 and reverse, 5-TTA CAG GAC ATT GCG AGC AG-3.
The protein-boundDNAwas calculated as a ratio to inputDNA.
The specificity of amplification using the primers above was as-
sessed by PCR amplification (30 cycles of 30 sec at 95 C, 30 sec
at 60C, and30 sec at 72C), electrophoreses on1.5%agarose gel,
and staining with ethidium bromide and visualization of the ex-
pected bands. For ChIP analysis of the endogenous RBP4 gene
promoter, we followed essentially the same procedures, but
HIB-1 cells were not transfected with the RBP4 promoter plas-
mids, and a DNA fragment, encompassing the corresponding
PPAR-responsive region in the mouse RBP4 gene promoter, was
amplified using the specific primers: forward, 5-GCTTCTACT
GAG GAG CTG TTG TG-3; and reverse, 5-GGA CGA TCA
ACC ACT CGG CCA TTG-3.
Where appropriate, statistical analysis was performed using
the Student’s t test; significance is indicated in the text.
Results
RBP4 gene expression and induction by
thermogenic activation in mouse BAT
Basal expression of RBP4 mRNAwas not significantly
different between BAT and WAT in mice reared at ther-
moneutral temperature. Exposure of mice to cold (4 C)
caused a significant increase in RBP4 mRNA levels in
BAT, whereas no effects were observed inWAT (Fig. 1A).
In fact, mice placed at the usual room temperature (21 C),
in which a mild thermogenic stimulus occurs, showed sig-
nificantly higher levels of RBP4 mRNA in BAT than in
WAT (3 0.25-fold, P 0.05), thus confirming the sen-
sitivity of the RBP4 gene to the thermogenic stimulus in
BAT. However, exposure of mice to a 4 C environment
caused a significant reduction in RBP4 gene expression in
the liver fromcold-exposedmice (6513%RBP4mRNA
levels respect to thermoneutral liver, P  0.05). Plasma
levels of RBP4were lowered in cold-exposedmice (54.5
4.6 g/ml) respect to thermoneutral controls (78.1 2.4
g/ml, P  0.05).
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The effects of acute treatment of mice with drugs dis-
tinct from a noradrenergic stimulus but known to influ-
encebrown fat activity, i.e. PPARactivators,were studied.
Previous studies have indicated that the action on BAT of
acute treatment of mice with PPAR activators was opti-
mally visualized when controls were mice in a physiolog-
ical state involving low levels of circulating free fatty acids,
i.e. lactating dams (19). Thus, when lactating mice were
treatedwith a single dose of bezafibrate, a PPAR activator
with poor selectivity for PPAR subtypes, a significant rise
in RBP4 mRNAwas observed (Fig. 1B). The PPAR-spe-
cific activator Wy14,643 also significantly induced RBP4
mRNAlevels.To further establish the roleofPPAR in the
control of RBP4 gene expression in BAT, PPAR-null
mice were studied. No differences in RBP4 mRNA levels
were observed in BAT from mice in basal, thermoneutral
conditions (Fig. 1C). However, cold exposure caused a
minor induction of RBP4 mRNA levels in PPAR-null
mice relative to controls (Fig. 1C), thus suggesting an in-
teraction between noradrenergic and PPAR-dependent
pathways of control of the RBP4 gene in BAT. In liver,
levels of RBP4 mRNA expression were lower in PPAR-
null respect towild-typemice in thermoneutral conditions
and were similarly lowered by cold exposure (Table 1).
Plasma levels of RBP4 in PPAR-null mice were reduced
respect towild-typemice in thermoneutral conditions and
after cold exposure (Table 1).
Effects of noradrenergic activation, PPAR agonists,
and retinoids on RBP4 gene expression in brown
adipocytes
Norepinephrine as well as cAMP caused a dramatic
induction of RBP4 mRNA levels in brown adipocytes in
primary culture. Bezafibrate, PPAR (GW7647), and
PPAR (rosiglitazone)-specific activators also signifi-
cantly induced RBP4 mRNA levels, whereas a PPAR/
activator (GW501516) did not (Fig. 2A). Both 9-cis reti-
noic acid and a synthetic activator of RXR, AGN194204
(a gift from R. Chandraratna), also increased RBP4
mRNA abundance. In contrast neither all-trans retinoic
acid nor TTNPB, a specific activator of RAR, induced
RBP4mRNAexpression.Toestablish the consequencesof
the increase in RBP4 mRNA levels, RBP4 protein levels
FIG. 1. RBP4 mRNA levels in brown and WAT. Effects of thermogenic
stimulus and PPAR-dependent stimulation. A, RBP4 mRNA levels in
BAT and WAT from Swiss mice maintained at thermoneutral
temperature (28 C) (TN) or exposed to 4 C ambient temperature
during 24 h. B, RBP4 mRNA levels in BAT from lactating mice 6 h after
treatment with a single injection of Wy14,643 (50 g/g bw) or
bezafibrate (100 g/g bw) (BZ). C, RBP4 mRNA levels in BAT from
PPAR-null and wild-type mice exposed to 4 C ambient temperature
over 24 h. Bars indicate the mean  SEM of six to seven mice from at
least three different litters. Data are shown as fold-induction relative to
control values for each panel. Significant differences between controls
and cold exposed (A and C) or with respect to drug-injected mice (B)
are shown by *, P  0.05; and the comparison between wild-type and
PPAR-null mice by #, P  0.05. DMSO, Dimethylsulfoxide.
TABLE 1. Plasma RBP4 levels and RBP4 mRNA
expression in liver from PPAR-null mice and
wild-type controls
Plasma RBP4
(g/ml)
Liver RBP4 mRNA
(% vs. thermoneutral
wild type)
Wild type
Thermoneutral 80  3 100  14
4 C, 24 h 55  4a 61  8a
PPAR-null
Thermoneutral 57  5b 62  5b
4 C, 24 h 43  2a,b 40  3a,b
Effects of cold exposure. Data are means  SEM of four to five mice.
a Statistically significance of differences due to cold exposure (4 C, 24 h);
P 0.05.
b Statistically significance of differences between PPAR-null and wild-
type controls at each thermal environment condition; P  0.05.
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were determined in brown adipocyte culturemedium. Re-
sults indicated that norepinephrine, cAMP, bezafibrate,
and the PPAR-specific (rosiglitazone) and PPAR-spe-
cific (GW7647) activators caused a significant rise in the
abundance of RBP4 protein in the medium (Fig. 2B).
To further analyze the role of PPAR in the control of
the RBP4 gene and its interaction with the cAMP-depen-
dent, noradrenergic pathway of regulation, primary cul-
tures of brown adipocytes were established from PPAR-
null mice (Fig. 3). Morphological differentiation of
adipocytes from PPAR-null mice was unaltered respect
to cultures from wild-type mice, as described elsewhere
(31). Basal levels of RBP4 mRNA expression were also
unaltered in PPAR-null brown adipocytes, whereas the
increase in RBP4 mRNA levels due to the PPAR agonist
GW7647 was completely suppressed (Fig. 3). The effects
of the RXR activator AGN194204 were essentially un-
changed, and theactionof9-cis retinoic acidandof rosigli-
tazone was slightly reduced. The effects of norepineph-
rine, although not completely impaired,were significantly
reduced in adipocytes lacking PPAR, thus further indi-
cating a cross talk between PPAR-dependent and nor-
adrenergic pathways of regulation of RBP4 gene expres-
sion (Fig. 3).
In a second approach, the PPAR antagonist GW6471
was used. This drug not only suppressed the action of the
PPAR activator GW7647, but it also significantly re-
duced the action of norepinephrine (Fig. 4). The PPAR
antagonist GW9662 also significantly decreased the ef-
fects of norepinephrine on RBP4 mRNA expression,
whereas treatmentwithbothPPARsubtype-specific drugs
completely suppressed noradrenergic induction. This in-
dicated that an active PPAR-dependent pathway of regu-
lation, either through PPAR or PPAR, is required for
effective noradrenergic induction of the RBP4 gene in
brown adipocytes.
Transcriptional control of the RBP4 gene by PPAR
and cAMP in brown adipocytes
To determine the action of cAMP and PPAR-depen-
dent pathways in transcriptional control of the RBP4 gene
in brown adipocytes, transfection assays on HIB-1B
FIG. 2. Effects of hormonal agents on RBP4 mRNA and RBP4 protein
levels in brown adipocytes differentiated in culture. A, RBP4 mRNA
levels in mouse brown adipocytes differentiated in primary culture and
exposed to the indicated agents (see Materials and Methods). B, RBP4
protein in culture medium from brown adipocytes differentiated in
culture. An example of immunoblot analysis of RBP4 (24 kDa) in cell
culture medium is shown in C, bottom panel. Cells were treated with 1
M GW7647, 10 M rosiglitazone (Rosi), 1 M GW501516, 100 M
bezafibrate (BZ), 1 M 9-cis retinoic acid (RA), 10 M AGN194202, 1
M all-trans retinoic acid, 10 M TTNPB, 0.5 M norepinephrine (NE),
or 1 mM dibutyryl-cAMP. Bars indicate the mean  SEM of four to six
independent cell cultures for each condition. Data are shown as fold-
induction relative to control (C, untreated cells) values for each panel.
Significant differences in comparison with controls are shown by
*, P  0.05.
FIG. 3. Responsiveness of RBP4 gene expression to hormonal agents
in brown adipocytes lacking PPAR. RBP4 mRNA levels in mouse
brown adipocytes obtained from wild-type and PPAR-null mice and
exposed to the indicated agents (see Fig. 2A). Bars indicate the
mean  SEM of four to six independent cell cultures for each condition.
Data are shown as fold-induction relative to values in nontreated cells
from wild-type mice. Significant differences between each treatment
condition and nontreated cells (C) for each genetic background are
indicated by *, P  0.05, and those between wild-type and PPAR-null
cells for each treatment condition by #, P  0.05. NE, Norepinephrine;
RA, retinoic acid; Rosi, rosiglitazone.
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brown fat-derived cells were performed using a luciferase
construct driven by the 1192-bp promoter region of the
human RBP4 gene. Exposure of the transfected construct
to PPAR activators indicated significant induction by
PPAR activation (rosiglitazone), aweaker but significant
induction by PPAR activation (GW7647), and a signif-
icant induction due to cAMP (Fig. 5A). Cotransfection
with PPAR, and particularly further addition of
GW7647, caused a dramatic induction of the RBP4 pro-
moter activity. Similar observations were obtained when
PPAR was cotransfected and cells were exposed to
rosiglitazone. No effects were observed with PPAR/
cotransfection, further indicating the lack of sensitivity of
the RBP4 gene to this PPAR subtype (data not shown).
Through a deletion mutant analysis, it was determined
that the RBP4 promoter construct lacking the fragment
from 1192 to 535 retained most of the basal activity
but became completely nonsensitive to PPAR-dependent
regulation (Fig. 5A).Most of cAMP-mediated responsive-
nesswas lost in this short535-RBP4-Luc construct. Fur-
ther deletion of the reporter construct between535 and
285 dramatically reduced basal promoter activity (11%
of the full-length construct levels), and 285-RBP4-Luc
was completely insensitive to PPAR- or cAMP-dependent
regulation (data not shown). The1192 to535 region
of the RBP4 gene was previously reported to contain a
putative PPAR-responsive sequence at 765 to 745
(27).Whenwe analyzed a construct of theRBP4promoter
in which point mutations had been introduced to disrupt
PPAR binding at this site (1192-Mut-RBP4-Luc) (Fig.
5C), the responsiveness to PPAR and to cAMPwas essen-
tially lost (Fig. 5A). ChIP in conditions of PPAR-depen-
dent inductionof theRBP4promoter inHIB-1B cells using
antibodies against PPAR and PPAR indicated a specific
enrichment in the PCR amplification of both the endog-
enous and the transfectedRBP4promoter region (Fig. 5B).
When 1192-Mut-RBP4-Luc mutated version of the
RBP4 promoter construct was analyzed in comparison
with the wild-type promoter construct, a significant im-
pairment in the enrichment of amplified DNA after ChIP
using PPAR and PPAR antibodies was observed (Fig.
5D). Collectively, this data indicate that PPAR and
PPAR regulate the RBP4 gene promoter mainly through
the 765 to 745 region of the RBP4 gene.
Regulation of RBP4 gene expression in white
adipocytes
We determined whether the observed effects were spe-
cific to brown adipocytes or were shared bywhite adipose
cells. Differentiated 3T3-L1 and 3T3-F442A adipocytes
express extremely low levels of RBP4 mRNA, hardly de-
tectable even using highly sensitive quantitative real-time
PCR. In contrast,mousewhite adipocytes differentiated in
primary culture expressed substantial levels of RBP4
mRNA. Norepinephrine and the PPAR agonist rosigli-
tazone significantly induced RBP4 mRNA levels in white
adipocytes, whereas the PPAR activator GW7647 had
no effect (Fig. 6A). Parallel observations were made for
RBP4 protein levels in the adipocyte culture medium in
response to these agents (Fig. 6B). The study of SGBS hu-
manwhite adipocytes led essentially to similar results (Fig.
6C). This indicated that the main features of regulation of
RBP4 gene expression in white adipocytes were shared by
human and murine cells.
The lack of effect observed for the PPAR agonist on
RBP4 gene expression in white adipocytes was likely to be
due to the much lower expression of PPAR in white, in
comparison with brown, adipocytes (18). We therefore
investigated whether increasing PPAR expression in
white adipocytes could confer to these cells sensitivity to
activation of RBP4 gene expression. Adenoviral transduc-
tionof humanSGBSwhite adipocytes led tohighly PPAR
expression, with levels around 30-fold those in basal con-
ditions. PPAR expression led to a significant inductionof
RBP4 mRNA levels in SGBS white adipocytes after expo-
sure to GW7647 (Fig. 6D). This confirmed the positive
action of PPAR on the RBP4 gene in the context of ad-
ipose cells, either brown or white.
Effects of PGC-1 on RBP4 gene regulation
The requirement of intact PPAR signaling pathway for
cAMP responsiveness of RBP4 gene expression led us to
study whether the effects of noradrenergic, cAMP-depen-
FIG. 4. Effects of PPAR and PPAR antagonists on RBP4 mRNA
expression in response to norepinephrine (NE) in brown adipocytes.
RBP4 mRNA levels in mouse brown adipocytes differentiated in primary
culture and exposed to norepinephrine in the presence or absence of
the PPAR antagonist GW6471 (10 M) and/or the PPAR-antagonist
GW9662 (30 M). Bars indicate the mean  SEM of four to six
independent cell cultures for each condition. Data are shown as fold-
induction relative to control (C, untreated cells) values for each panel.
Significant differences in comparison with controls are shown by
*, P  0.05 and those for the effects of NE in the presence of
antagonist relative to its absence by #, P  0.05. Rosi, Rosiglitazone.
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dent, stimulusof theRBP4gene inbrownadipocytes could
occur through indirect processes.Treatmentof brownadi-
pocytes with cycloheximide, a suppressor of protein syn-
thesis, bluntedRBP4mRNA induction in response to nor-
epinephrine (Fig. 7A), indicating that, effectively, RBP4
mRNA induction was protein-synthesis dependent. We
examined the role of PGC-1 in RBP4 gene regulation in
brown adipocytes, considering that PGC-1 expression is
induced by norepinephrine in brown adipocytes via
cAMP-dependent signaling and it is a powerful coactiva-
tor of PPAR and PPAR (32). The time course of nor-
epinephrine effects on gene expression in brown adi-
FIG. 5. Effects of PPAR and PPAR activation and of cAMP on RBP4 promoter. A, HIB-1B cells were transfected with the 1192-RBP4-Luc
plasmid, the deleted plasmid construct 535-RBP4-Luc, or the 1192 hRBP4-Mut-Luc mutated version (see C) and, when indicated, were
cotransfected with the plasmid expression vectors for PPAR or PPAR and exposed to the PPAR activator GW7647, the PPAR activator
rosiglitazone, and 1 mM dibutyryl-cAMP (cAMP). Bars indicate the mean  SEM of normalized luciferase activity (see Materials and Methods).
Significant differences (P  0.05) due to PPAR agonists or cAMP relative to controls for each construct and cotransfection setting are shown by
*, those due to PPAR or PPAR for each condition are shown by #, and those between wild-type and mutated forms of the promoter constructs
at the same condition are shown by . B, ChIP of PPAR and PPAR binding to RBP4 gene promoter. HIB-1B cells were analyzed without
transfection of promoter constructs (analysis of the endogenous murine RBP4 gene promoter) or after transfection with the 1192-RBP4-Luc.
PPAR and PPAR expression vectors were cotransfected, and cells were treated with 1 M GW7647 and 10 M rosiglitazone (Rosi), respectively.
PPAR or PPAR antibodies (Ab) or an unrelated IgG were used to immunoprecipitate the protein-DNA complexes. Bars are mean  SEM of relative
enrichment of the PCR amplification signals due the PPAR antibodies respect to IgG (top). Significant differences respect to IgG are shown by
*, P  0.05. An example of PCR amplification in the ChIP assay is shown (bottom). RBP4 indicates the amplified DNA corresponding to the RBP4
promoter region, and Cyp, that corresponding to the cyclophilin-A gene used as control (see Materials and Methods). C, Sequence of the PPAR
responsive element in the RBP4 promoter; site-directed mutations to generate 1192-RBP4-Mut-Luc are shown in lower case. D, ChIP of PPAR and
PPAR binding to the wild-type and mutant forms of the RBP4 gene promoter. HIB-1B cells were transfected and treated as in B but including
either the 1192-RBP4-Luc or 1192-RBP4-Mut-Luc plasmids. Bars are mean  SEM of relative enrichment of the PCR amplification signal respect
to input. Significant differences between the wild-type (wt) and the mutated (mut) promoter constructs are shown by *, P  0.05.
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pocytes showed a much earlier peak of induction of
PGC-1 mRNA than RBP4 mRNA (Fig. 7B). Cyclohex-
imide did not suppress PGC-1mRNA induction (17-fold
induction of PGC-1mRNA in the presence of cyclohex-
imide vs.15-fold induction in the absence, 2-h exposure to
norepinephrine). These results were compatible with the
hypothesis that PGC-1may play a role in stimulus of the
RBP4 gene in response to noradrenergic cAMP-mediated
signaling, via coactivation of PPAR. This possibility was
assessed by determining the effects of impairing PGC-1
expression in the responsiveness of the RBP4 gene to nor-
epinephrine. Adenoviral-mediated expression of PGC-1
small interfering RNA (siRNA) reduced PGC-1 mRNA
levels to 31 5% respect to those in controls transduced
with scrambled siRNA. Under these conditions, the ca-
pacity of norepinephrine to induce RBP4 mRNA expres-
sion was significantly impaired (Fig. 7C). The role of
PGC-1 inmediatingRBP4 gene expressionwas explored
further by studying the effects of cAMP on adipocytes
derived fromMEF obtained fromwild-type and PGC-1-
null mice. Adipocytes from wild-type MEF exhibit an in-
termediate brown-to-white adipocyte phenotype, includ-
ing the expression of substantial levels of PGC-1 (see
Refs. 26, 33 and present results). After adipogenic differ-
entiation, MEF from wild-type and from PGC-1-null
mice acquired adiposemorphology and expressedmarker
genes of adipogenesis, such as ap2mRNAor PPAR (data
not shown) similarly, as expected from a previous report
using RNA interference-mediated PGC-1 invalidation
systems (34). Basal expression of RBP4 mRNA was
slightly impaired in PGC-1-null adipocytes (71  28%
respect to wild-type adipocytes). Adipocytes derived from
PGC-1-null embryos showed a significant impairment in
cAMP-mediated induction of RBP4 mRNA expression
(Fig. 7D), thus indicating that PGC-1 is required for
cAMP-mediated regulation of the RBP4 gene. A further
analysis using transfection of HIB-1B cells was under-
taken. PGC-1 cotransfection induced RBP4 gene pro-
moter activity aswell as enhanced theactivationelicitedby
rosiglitazone and PPAR cotransfection (Fig. 7E). Similar
results were observed for PPAR and GW7647 effects
(data not shown). The effects of PGC-1 cotransfection
were lost for the 1192 hRBP4-Mut-Luc construct, in
which the PPAR responsive region is mutated. Finally, the
FIG. 6. Effects of hormonal agents on RBP4 mRNA and protein levels in murine white adipocytes differentiated in primary culture and in
differentiated human SGBS white adipocytes. A, RBP4 mRNA levels in mouse white adipocytes differentiated in primary culture and exposed to the
indicated agents (see Materials and Methods). B, RBP4 protein in culture medium from white adipocytes differentiated in culture. C, RBP4 mRNA
levels in human SGBS white adipocytes differentiated in culture and exposed to the indicated agents and concentrations (see legend to Fig. 2). D,
RBP4 mRNA levels in human SGBS white adipocytes differentiated in culture and transduced with adenoviral vectors driving PPAR or GFP as a
control and treated or not with the PPAR activator GW7647 (1 M). Bars indicate the mean  SEM of four to six independent cell cultures for
each condition. Data are shown as fold-induction relative to control (C, untreated cells) values for each panel. Significant differences in comparison
with controls are shown by *, P  0.05. NE, Norepinephrine; Rosi, rosiglitazone.
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effects of PGC-1onRBP4gene expressionwere analyzed
in SGBS white adipocytes, which lack a substantial ex-
pressionof PGC-1 in contrastwithbrownadipocytes but
express PPAR. Adenoviral-mediated overexpression of
PGC-1 was enough to cause a significant induction of
RBP4 mRNA expression (Fig. 7F).
Discussion
The present study demonstrates that RBP4 gene expres-
sion is tightly regulated in BAT by cAMP-mediated
pathways, PPAR and PPAR. Moreover, the present
findings supports the notion that, in contrast to other
adipokines that are preferentially released by white
(rather than brown) adipocytes, substantial RBP4 ex-
pression and release occurs in BAT, specially after ther-
mogenic activation.
The cAMP-dependent regulation observed in brown
adipocytes may be related to the induction of RBP4 gene
expression by the thermogenic stimulus in BAT. A likely
scenario after thermogenic stimulus would be that en-
hanced lipolysis results in increased hydrolysis of retinyl-
esters inside the fat depots of BAT, with the subsequent
release of retinol and the potential need for coordinate
synthesis of the RBP4 protein to bind it. The capacity of
BATtobecomeanenhanced sourceof retinol and/orRBP4
protein in response to thermogenic stress has not been
analyzed to date, but it might be expected to occur on the
basis of the present findings. However, the physiological
significance ofRBP4 expression and release by BATunder
conditions of enhanced thermogenic activity is unclear at
present. We observed that serum RBP4 levels were re-
duced inmice exposed to cold, in associationwith reduced
RBP4geneexpression in liver. Ingeneral, changes in serum
FIG. 7. Regulation of PGC-1 gene expression and effects of PGC-1 on RBP4 gene expression. A, Effects of cycloheximide (5 g/ml) treatment
on the changes in RBP4 mRNA elicited by norepinephrine (0.5 M). Data are expressed as fold induction relative to 0 h. B, Time course of changes
in PGC-1 mRNA and RBP4 mRNA expression in brown adipocytes differentiated in primary culture after norepinephrine treatment (0.5 M). Data
are expressed as fold-induction relative to 0 h. A and B, Points are means from two to three independent experiments with triplicate plates, in
which the variation within the experimental groups was less than 15%. C, Brown adipocytes were transduced with an adenoviral vector driving
PGC-1 siRNA or an adenoviral vector driving scrambled siRNA (control siRNA) and exposed or not to 0.5 M norepinephrine (NE) for 6 h. Bars are
mean  SEM of relative RBP4 mRNA levels in four independent assays. Statistical differences due to NE in each condition are shown as *, P  0.05
and those due to PGC-1 siRNA as #, P  0.05. D, Adipocytes derived from MEF from PGC-1-null and wild-type littermates were exposed to 1
mM dibutyryl-cAMP for 3, 6, and 24 h, and induction of RBP4 mRNA expression was expressed as mean  SEM. Statistical differences between
PGC-1-null and wild-type adipocytes are shown as *, P  0.05. E, HIB-1B cells were transfected with the 1192-RBP4-Luc or 1192-RBP4-Mut-
Luc plasmids and, when indicated, cotransfected with the plasmid expression vectors for PPAR or PGC-1 and exposed to the PPAR activator
rosiglitazone (Rosi). Bars indicate the mean  SEM of normalized luciferase activity. Significant differences (P  0.05) in comparison with controls
are shown by *, those due to both PPAR and PGC-1 are shown by #, and those between wild-type and mutated form of the promoter at the
same condition are sown by . F, RBP4 mRNA levels in SGBS human white adipocytes differentiated in culture transduced with adenoviral vectors
driving PGC-1, or GFP as a control. Bars indicate the mean  SEM of RBP4 mRNA levels for four to five independent cell cultures for each
condition. Data are expressed as fold-induction relative to nontreated, nonadenoviral-transduced cells (C).
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RBP4 levels paralleled changes in liver RBP4 expression in
our study, thus supporting a main role of liver RBP4 ex-
pression in determining circulating RBP4 levels. It is likely
that lowered hepatic expression compensate for enhanced
RBP4 production by BAT in conditions of thermogenic
stress resulting ultimately in lower systemic levels. The
possibility that increased production of RBP4 by BAT
causesmainly local, autocrine/paracrine effects should de-
serve further research. In WAT, adrenergic induction of
RBP4 gene expression and release might have a distinct
physiological significance, because lipolysis in white fat is
enhanced in response to starvation, a state of increased
RBP4 levels in serum and reduced insulin action.
Our present findings indicate that PPAR activation
induces RBP4 expression by acting directly on the RBP4
gene promoter. This is in agreement with reports on the
action of the PPAR-activating drugs pioglitazone and
troglitazone in human adipocytes in culture (8, 21). How-
ever, the effects of treatment with TZD on patient RBP4
levels are controversial, given currently conflictingdataon
the role of RBP4 in obesity and development of insulin
resistance and type II diabetes (for a review of the current
state of the controversies, see 35). Lowered serum RBP4
levels have been reported after treatment of diabetic (36,
37) andHIV-1-infected (38) patients with pioglitazone or
rosiglitazone. However, other studies did not record a sig-
nificant reduction after pioglitazone treatment (39, 40). In
mice, chronic treatment with rosiglitazone lowers RBP4
serum levels but only in insulin-resistant mice (3). In pa-
tients, a single recent report showed increasedRBP4 levels
in WAT from pioglitazone-treated patients (8). The ap-
parently contradictory observations of a positive impact
of TZDonRBP4 gene expression in adipose tissues shown
here, and the lowered RBP4 circulating levels in several
reports of TZD-treated patients, may be due to the com-
plex turnover processes determiningRBP4 levels in serum,
for which release from adipose tissues is just one more
component. Indirect effects of TZDonnonadipose sites of
RBP4 release, or on degradation and renal clearance of
RBP4, cannot be excluded and warrant further research.
In any case, a direct antidiabetic action of TZD via reduc-
tion of RBP4 release by adipose cells is unlikely in light of
the present findings.
The present results identify a novel pathway of regu-
lation of RBP4 gene expression by the recognition of
PPAR, and the corresponding activating drugs, as a pow-
erful activators of RBP4 gene expression and release by
brown adipocytes, the type of adipose cell with preferen-
tial expression of PPAR. The fact that the RBP4 gene is
part of the cluster of PPAR-regulated genes, usually en-
coding lipid catabolism proteins, may be related to the
aforementioned need for dealing with the free retinol ap-
pearing in BAT as a consequence of a high lipolysis during
thermogenic activation. On the other hand, the identifi-
cation of the RBP4 gene as a target of PPAR in brown
adipocytes should lead to exploration of whether this
pathway is also active in liver, a main site of PPAR and
RBP4 gene expression, and a major target of fibrates,
PPAR-activating drugs of current use in some dyslipi-
demias.Ourpresent data indicating lowered expressionof
RBP4 mRNA in liver from PPAR-null mice is consistent
with this possibility. In a recent study, chronic treatment
of obese mice with the PPAR agonist fenofibrate was
reported to cause a reduction of RBP4 mRNA expression
in WAT (41), although it is unclear whether this was a
direct or indirect effect as a consequence of long-term
treatment “in vivo.” In that report, the action of fenofi-
brate causing a slight decline in RBP4 mRNA expression
in 3T3-L1 adipocytes should be considered to the light of
the present findings and other previous reports (42) indi-
cating an extremely lowbasal expressionofRBP4, close to
detection limits, in 3T3-L1 adipocytes.
A close interplay between the cAMP and PPAR-depen-
dent pathways of regulation of the RBP4 gene in BAT is
shown in the present study, and most of the cAMP action
on RBP4 gene transcription requires intact PPAR-depen-
dent pathways. A role for PPAR in mediating noradren-
ergic, cAMP-dependent, regulation of gene transcription
in BAT has been proposed (43, 44), and it was attributed
to the action of cAMP in promoting lipolysis and the in-
tracellular generationof free fatty acid derivatives, natural
activators of PPAR. However, modulation of PPAR ac-
tivity via protein kinase A-dependent phosphorylation
cannot be excluded (45). Nonetheless, our present data
strongly support that it is PGC-1 inductionby cAMPand
the corresponding action of PGC-1 in coactivating
PPAR and/or PPAR what determines most of the
cAMP-dependent RBP4 gene regulation.
In summary,we report that PPAR and PPAR, aswell
as cAMP, control RBP4 gene expression in brown adi-
pocytes. Induction of PGC-1 expression by cAMP and
subsequent coactivation of PPAR play a pivotal role in
mediating cAMP effects. Drugs activating PPAR, such as
TZD, promote RBP4 gene up-regulation in adipocytes.
Fibrates, which act on PPAR, also control RBP4 gene
expression in brown adipocytes. Taking into account the
recent recognition of active BAT in adult humans (12),
further researchwill be required to establish the role of the
induction of RBP4 gene expression and RBP4 protein re-
lease by BAT in the context of the overall systemic respon-
siveness to these drugs when used in the treatment of in-
sulin resistance and dyslipidemias.
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